Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
25 July, 2017 20:19 IST
Piramal Enterprises concludes acquisition of drug portfolio from Mallinckrodt
Source: IRIS | 20 Mar, 2017, 10.28AM
Comments  |  Post Comment

Piramal Enterprises, one of India's largest diversified companies with a presence in pharmaceutical, financial services, announced that its wholly owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (Mallinckrodt).

As indicated in the Press Release dated January 30, 2017, the acquisition was for a cash consideration of USD 171 million and up to an additional USD 32 million payable depending on financial performance of the acquired assets over the next three years.

The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen has also been approved for launch in eight European markets.

Gablofen is the only intrathecal baclofen drug available in vials and pre-filled syringes, which are preferred by users over the competing products available in ampoules. The pain management drugs under development are also for intrathecal administration. In the twelve months ending September 30, 2016, the acquired portfolio generated revenues of USD 44.6 million.

Shares of the company gained Rs 9.25, or 0.5%, to trade at Rs 1,871.90. The total volume of shares traded was 217 at the BSE (10.17 a.m., Monday).



Piramal Enterprises Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Aurionpro's arm inks pact with HPE for powering Isla - 25-Jul-2017 13:21
Unichem gets ANDA approval for Losartan Potassium, Hydrochlorothiazide tablets - 25-Jul-2017 13:18
Zydus receives final approval from USFDA for Mesalamine Delayed-Release Tablets - 25-Jul-2017 13:14
Ambuja Cements quarterly net up 12% - 25-Jul-2017 10:23
Ratnamani Metals bags two new orders worth Rs 3.39 bn - 25-Jul-2017 10:14
Welspun Enterprises to expand infrastructure operations - 25-Jul-2017 10:09
Wipro partners HPE to offer IT Infra Solutions - 25-Jul-2017 10:03
Glenmark gets final approval from USFDA for Desonide Cream - 25-Jul-2017 09:50
Reliance Nippon Life Asset Management reports significant growth in AUM in Q1FY18 - 25-Jul-2017 08:44
Moody's affirms ratings of seven and downgrades ratings of two Indian public sector banks - 24-Jul-2017 16:28
Moody's affirms ratings of seven and downgrades ratings of two Indian public sector banks - 24-Jul-2017 16:28
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer